{
    "clinical_study": {
        "@rank": "109139", 
        "arm_group": {
            "arm_group_label": "Vitamin D", 
            "arm_group_type": "Experimental", 
            "description": "Vitamin D supplementation at 100,000 IU once a month for 3 months"
        }, 
        "brief_summary": {
            "textblock": "Vitamin D deficiency has been linked to endothelial dysfunction in adults. Obese adolescents\n      have a high prevalence of Vitamin D deficiency as well as evidence of endothelial\n      dysfunction. Our hypothesis is that supplementation of Vitamin D deficient adolescents with\n      Vitamin D would lead to improvement in endothelial dysfunction."
        }, 
        "brief_title": "Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Obesity", 
            "Endothelial Dysfunction", 
            "Vitamin D Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Vitamin D Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 12-18 years\n\n          2. BMI >95% for age and gender\n\n          3. 25 (OH) D levels less than 30 ng/ml\n\n        Exclusion Criteria:\n\n          1. 25 (OH) D levels  >30 ng/mL\n\n          2. Serum calcium >10.4 mg/dL\n\n          3. Serum phosphorus > 4.7 mg/dl\n\n          4. Pregnancy or nursing\n\n          5. Current cancer\n\n          6. Patients on vitamin D3 supplementation exceeding 400 IU/day\n\n          7. Hypertension defined as Blood Pressure over the 95th percentile for age, gender and\n             height\n\n          8. Dietary calcium intake exceeding 1500 mg/day,\n\n          9. Hepatic or renal disorders\n\n         10. Type 1 or type 2 diabetes mellitus\n\n         11. Subjects receiving insulin, metformin, or oral hypoglycemic medications\n\n         12. Subjects with malabsorption disorders (celiac disease, cystic  fibrosis,inflammatory\n             bowel disease)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746264", 
            "org_study_id": "12-006349"
        }, 
        "intervention": {
            "arm_group_label": "Vitamin D", 
            "description": "Vitamin D 3 at 100,000 IU once a month for 3 months", 
            "intervention_name": "Vitamin D3", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Endothelial dysfunction", 
            "Vitamin D deficiency"
        ], 
        "lastchanged_date": "May 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Seema Kumar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Endothelial function will be assessed by FMD.  Flow mediated dilatation (FMD) will be calculated as the maximal percentage increase in Brachial artery diameter (BAD) from baseline after the release of cuff occlusion.", 
            "measure": "Change in flow mediated dilatation (FMD)", 
            "safety_issue": "No", 
            "time_frame": "baseline to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746264"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Seema Kumar", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}